The MHRA and research peptides: what suppliers must not do

The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK regulator that decides whether a product is being sold as a medicine and takes action when an unlicensed one is. It does not license research peptides, because research peptides sold as laboratory reagents are not medicines; it does investigate suppliers whose presentation crosses the line. This note sets out, from the perspective of a compliant supplier, what the MHRA looks for, the behaviours that attract enforcement, and how Alphex keeps on the right side of them. It is general information, not legal advice. All Alphex products are for laboratory and in-vitro research only.

What the MHRA does and does not do here

• It does not approve, register or license research peptides or their suppliers. There is no MHRA "certification" for a research reagent, and any supplier claiming one is misrepresenting.
• It does determine, on the facts, whether a product is being presented or supplied as a medicine, and if so whether it is authorised.
• It does take enforcement action (warning letters, seizures, prosecution) against the sale and advertising of unlicensed medicines, and has done so against peptide sellers whose presentation crossed the line.

Behaviours that attract enforcement

1. Describing effects in people. Any statement, however hedged, that the product does something in humans (heals, repairs, improves, boosts, reduces) is a medicinal presentation.
2. Dosing and administration information for humans or animals: "protocols", cycles, injection guidance, reconstitution instructions framed for use rather than for the bench.
3. Consumer-style presentation: bundles with syringes and swabs, "kits", pre-filled devices, before-and-after imagery, testimonials describing personal use.
4. Implied claims by association: naming conditions, linking research-use products to therapeutic categories, or reproducing clinical claims from elsewhere as marketing.
5. Selling to consumers as consumers: no research-use restriction, no confirmation at purchase, marketing aimed at the public rather than laboratories.
6. Misleading quality claims (fabricated COAs, "pharmaceutical grade", "MHRA approved") which engage consumer protection law and the Digital Markets, Competition and Consumers Act 2024 alongside medicines law.

What compliant looks like

• Products described as laboratory reagents, with chemistry, specification, handling and analytical data.
• Research literature described neutrally, as literature, without adopting its findings as claims for the product.
• Handling guidance framed for the bench (reconstitution for assay work, storage of stocks), never for administration.
• Research-use-only statement on every product page, label and invoice; confirmation at checkout; declining orders that indicate otherwise.
• Verifiable quality claims: real COAs, named laboratory, batch matching, and no invented certifications.

Alphex's listings, specification tables and research notes are written to that standard, and where we describe a compound's research literature we say what it is (exploratory, preclinical) and what it is not (a basis for any use outside the laboratory). See what a compliant peptide listing looks like and research peptides and UK advertising rules.

Why this matters to the researcher

A supplier who markets to consumers with medicinal claims is a supplier whose business can be shut down or whose stock can be seized, which is a continuity risk for any laboratory relying on them. It is also a strong proxy for the rest of their practice: a seller who fabricates the legal position is more likely to fabricate the certificate. Compliance is a quality signal, and it is one of the twelve items in the supplier checklist.

Frequently asked questions

Can a supplier be "MHRA registered"?

Wholesale dealers and manufacturers of medicines hold MHRA licences. A research reagent supplier does not need one and cannot obtain one for research peptides. Treat the claim as a red flag.

Does the MHRA police what researchers do with the material?

Not in the laboratory. Research is governed by its own frameworks (institutional ethics, ASPA for animal work). The MHRA's interest is in supply and presentation to the public.

Where is the framework set out?

See the Human Medicines Regulations and research peptides and UK research peptide compliance.

Sources and further reading

• MHRA: A guide to what is a medicinal product (Guidance Note 8), GOV.UK: how the MHRA decides whether a product is a medicine by presentation and function
• The Human Medicines Regulations 2012 (SI 2012/1916), legislation.gov.uk: the UK medicines framework; regulation 2 defines a medicinal product
• CAP Code (UK non-broadcast advertising code), ASA: rules 3 (misleading advertising) and 12 (medicines and health)
• Digital Markets, Competition and Consumers Act 2024, legislation.gov.uk: unfair commercial practices including fake reviews and misleading price claims

This note is general information and is not legal advice. Alphex research peptides are supplied for laboratory and in-vitro research by qualified researchers only. They are not authorised for human or veterinary use.

Research use only. Alphex products are supplied exclusively for laboratory and in-vitro research by qualified researchers. They are not authorised for human or veterinary use, and nothing in this note is advice on any such use.

Published 20 May 2026, last reviewed 16 August 2026. Alphex reviews research notes when the testing method, the catalogue or UK guidance changes.

Alphex Research Team

Alphex Limited, UK research peptide supplier

The Alphex research team writes and maintains these notes for UK laboratories buying research peptides. Every batch Alphex lists is verified by reverse-phase HPLC with a batch-matched Certificate of Analysis. Content covers laboratory and in-vitro research only.